Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 184,844 | 51,870 | 42,925 | 90,466 | 149,800 |
| Receivables | 47,031 | 34,368 | 39,290 | 40,284 | 51,581 |
| Inventories | 15,610 | 16,243 | 15,691 | 21,568 | 36,628 |
| TOTAL | $252,955 | $113,831 | $118,149 | $185,182 | $271,149 |
| Non-Current Assets | |||||
| PPE Net | 1,222 | 2,200 | 3,629 | 5,214 | 6,754 |
| Intangibles | 59,044 | 59,044 | 95,086 | 131,128 | 167,171 |
| Other Non-Current Assets | 63,344 | 45,595 | 24,839 | 34,530 | 84,273 |
| TOTAL | $123,610 | $106,839 | $123,554 | $170,872 | $258,198 |
| Total Assets | $376,565 | $220,670 | $241,703 | $356,054 | $529,347 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 17,500 | 32,000 | 97,543 |
| Accounts payable and accrued liabilities | 21,185 | 15,180 | 14,635 | 18,021 | 33,588 |
| Accrued Expenses | 121,716 | 63,460 | 67,735 | 75,777 | 109,014 |
| Other current liabilities | 17,356 | 2,274 | N/A | N/A | N/A |
| TOTAL | $162,938 | $80,914 | $99,870 | $129,536 | $261,051 |
| Non-Current Liabilities | |||||
| Long Term Debt | 48,250 | 38,693 | 17,183 | 34,078 | 0 |
| Deferred Revenues | 2,681 | 0 | N/A | 3,738 | 20,906 |
| Other Non-Current Liabilities | 132,767 | 150,248 | 111,938 | 143,914 | 172,814 |
| TOTAL | $181,017 | $188,941 | $172,417 | $221,288 | $194,288 |
| Total Liabilities | $343,955 | $269,855 | $272,287 | $350,824 | $455,339 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 267,879 | 236,231 | 209,372 | 184,248 | 181,231 |
| Common Shares | 2 | 2 | 2 | 2 | 1 |
| Retained earnings | -1,683,705 | -1,678,360 | -1,608,950 | -1,557,025 | -1,462,799 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $32,610 | $-49,185 | $-30,584 | $5,230 | $74,008 |
| Total Liabilities And Equity | $376,565 | $220,670 | $241,703 | $356,054 | $529,347 |